Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment
Phase II Randomized Placebo-Controlled Clinical Trial of Genistein in Reducing the Toxicity and Improving the Efficacy of Intravesical Therapy
Sponsor: Emory University
A PHASE2 clinical study on Bladder Cancer, this trial is completed. The trial is conducted by Emory University and has accumulated 17 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
17 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE2
-
Mar 2025 — Mar 2026 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 12 earlier versions
-
Jun 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
-
Jan 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Dec 2019 — Dec 2020 [monthly]
Recruiting PHASE2
-
Dec 2018 — Dec 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jul 2017 — Nov 2017 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Jul 2017 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Emory University
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
- dsm-firmenich Switzerland AG
For direct contact, visit the study record on ClinicalTrials.gov .